PDF, Patent Landscape Report on Atazanavir - WIPO

More documents

Recommendations

Info

SECTION 8: DRUG COMBINATIONSCOMBINATION TYPES“Combination” is a term of art in drug development and this specific word reliably appears inpatent applications that cover a drug therapy that involves more than one bioactive agent.The types of drug combinations may differ, and common ones are diagrammed in Figure37.Figure 27 Types of CombinationsThere are some combinations aimed at preventing development of drug resistance(biochemical or genetic adaptation), others aimed at preventing drug degradation (meaningthat less drug would be required for therapeutic effect), and still others meant to mitigateunavoidable side-effects caused by the drug. All have been employed in the case ofAtazanavir. The overlap in the diagram is meant to convey that some combinations havemore than one strategy behind them, and also that there may be combinations that employmore than 2 therapeutic entities.Examples for some combination types are provided on the following pages, followed by anoverlap matrix that allows each kind of combination to be identified.42
TWO DRUGS DIRECTED AT THE SAME TARGETMultiple drugs exist in the HIV-protease inhibitor class. Drugs affecting the same target inthe HIV replication pathway are often used together to reduce the ability of HIV to developdrug resistance by developing variants. Treating with two drugs attacking the same targetreduces the chances that effective variants will arise, or as in the example shown in Figure38, help to overcome resistance that has begun to develop.Figure 38. Combination using two PI drugs and aimed at rescue43
Page 4 and 5: ContentsSECTION 1: THE TWO OBJECTIV
Page 7 and 8: collection for nuggets of intellige
Page 9 and 10: CHEMICAL NAMINGChemical naming conv
Page 11 and 12: Figure 2: Legal Status for Novartis
Page 13 and 14: name, but after the patent protecti
Page 15 and 16: STAGE TWO CLINICAL SEARCHTo be more
Page 17 and 18: CLINICAL COLLECTIONThis is an examp
Page 19 and 20: THE FOUNDER PATENT AND ITS DOWNSTRE
Page 21 and 22: CHEMICAL COLLECTIONThis is an examp
Page 23 and 24: SECTION 5: GENERAL OVERVIEW OF THE
Page 25 and 26: FAMILY MEMBER COUNTRIESLooking at p
Page 27 and 28: The crossover between categories is
Page 29 and 30: THE DEVELOPER’S OWN TIMELINEThe A
Page 31 and 32: Several of the representative paten
Page 33 and 34: Figure 25. Emphasis Matrix for Sele
Page 35 and 36: PATENT QUALITY INDICATORS FOR SELEC
Page 37 and 38: Figure 30. References made by the F
Page 39 and 40: FORMULATIONSEven before a drug is a
Page 41 and 42: Figure 34. References to Bristol My
Page 43: PROPRIETARY DRUGS AND LITIGATIONThe
Page 47 and 48: Citations to this document mainly c
Page 49 and 50: USING OVERLAP TO FIND COMBINATIONS
Page 51 and 52: INTERNATIONAL PATENT CLASSIFICATION
Page 53 and 54: ased on the IPC, but with sometimes
Page 55 and 56: DERWENT MANUAL CODESDWPI Manual Cod
Page 58: For more information contact WIPO a

PDF, Patent Landscape Report on Atazanavir - WIPO

Create successful ePaper yourself

Delete template?

Save as template?